Premium
Normal pregnancy outcome after first‐trimester exposure to liraglutide in a woman with Type 2 diabetes
Author(s) -
Greco D.
Publication year - 2015
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.12726
Subject(s) - liraglutide , medicine , pregnancy , gestation , diabetes mellitus , type 1 diabetes , type 2 diabetes , obstetrics , first trimester , pediatrics , endocrinology , biology , genetics
Background Data from animal studies suggest that glucagon‐like peptide‐1 analogues should not be used in pregnancy, but there have been no reports to date of their effects in human pregnancy. The aim of the present report was to describe a case of exposure to liraglutide during the first trimester of pregnancy in a patient with Type 2 diabetes mellitus. Case report A 37‐year‐old woman with Type 2 diabetes mellitus who had been taking liraglutide for 2 years was admitted in the 13 th week of gestation. Liraglutide was immediately discontinued and intensive insulin therapy instituted. The woman gave birth to a healthy child after completing an uneventful gestation period. Conclusion Although the present normal pregnancy outcome does not mean that glucagon‐like peptide‐1 analogues are safe to use in pregnancy, this report contributes to the limited knowledge regarding human exposure to these drugs during pregnancy in women with diabetes.